{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:53:02Z","timestamp":1790751182929,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.ymgme.2017.08.011","type":"journal-article","created":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T23:16:21Z","timestamp":1504221381000},"page":"39-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Quantitation of phenylbutyrate metabolites by UPLC-MS\/MS demonstrates inverse correlation of phenylacetate:phenylacetylglutamine ratio with plasma glutamine levels"],"prefix":"10.1016","volume":"122","author":[{"given":"Yi","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Almannai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. Reid","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8270-3943","authenticated-orcid":false,"given":"Qin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah H.","family":"Elsea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2017.08.011_bb0005","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ymgmr.2015.11.002","article-title":"Protein and calorie intakes in adult and pediatric subjects with urea cycle disorders participating in clinical trials of glycerol phenylbutyrate","volume":"6","author":"Hook","year":"2016","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2017.08.011_bb0010","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1136\/adc.86.1.54","article-title":"Neurological outcome of patients with ornithine carbamoyltransferase deficiency","volume":"86","author":"Nicolaides","year":"2002","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.ymgme.2017.08.011_bb0015","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/hbm.21470","article-title":"Altered neural activation in ornithine transcarbamylase deficiency during executive cognition: an fMRI study","volume":"34","author":"Gropman","year":"2013","journal-title":"Hum. Brain Mapp."},{"key":"10.1016\/j.ymgme.2017.08.011_bb0020","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1478-3231.2011.02698.x","article-title":"Reduction in hyperammonaemia by ornithine phenylacetate prevents lipopolysaccharide-induced brain edema and coma in cirrhotic rats","volume":"32","author":"Wright","year":"2012","journal-title":"Liver Int."},{"key":"10.1016\/j.ymgme.2017.08.011_bb0025","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s00431-003-1188-9","article-title":"Outcome and survival of 88 patients with urea cycle disorders a retrospective evaluation","volume":"162","author":"Claude","year":"2003","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymgme.2017.08.011_bb0030","article-title":"Suggested guidelines for the diagonisis and management of urea cycle disorders","volume":"7","author":"H\u00e4berle","year":"2012","journal-title":"Otphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2017.08.011_bb0035","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ymgme.2011.04.013","article-title":"Ammonia control in children with urea cycle disorders (UCDs); phase 2 comparison of sodium phenylbutyrate and glycerol phenylbutyrate","volume":"103","author":"Lichter-Konecki","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2017.08.011_bb0040","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ymgme.2010.03.014","article-title":"Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control","volume":"100","author":"Lee","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2017.08.011_bb0045","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1002\/hep.26058","article-title":"Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate","volume":"57","author":"Diaz","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.ymgme.2017.08.011_bb0050","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ymgme.2012.08.006","article-title":"Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders","volume":"107","author":"Mokhtarani","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2017.08.011_bb0055","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/clinchem\/47.2.351","article-title":"Quantification of BA, PAA, PBA from filter paper blood spots by gcms with stable isotope dilution","volume":"47","author":"Yu","year":"2001","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ymgme.2017.08.011_bb0060","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1006\/abio.1993.1323","article-title":"Assay of the human liver citric acid cycle probe phenylacetylglutamine and of phenylacetate in plasma by GC-MS","volume":"212","author":"Yang","year":"1993","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ymgme.2017.08.011_bb0065","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ymben.2009.08.009","article-title":"Contribution of proteolytic and metabolic sources to hepatic glutamine by 2H NMR analysis of urinary phenylacetylglutamine 2H-enrichment from 2H2O","volume":"12","author":"Barosa","year":"2010","journal-title":"Metab. Eng."},{"key":"10.1016\/j.ymgme.2017.08.011_bb0070","doi-asserted-by":"crossref","first-page":"S321","DOI":"10.1007\/s10545-010-9172-9","article-title":"Simultaneous LC-MS\/MS determination of phenylbutyrate, phenylacetate benzoate and their corresponding metabolites phenylacetylglutamine and hippurate in blood and urine","volume":"33","author":"Laryea","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2017.08.011_bb0075","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1039\/C1AY05427A","article-title":"Quantitative UPLC-MS\/MS analysis of the gut microbial co-metabolites phenylacetylglutamine, 4-cresyl sulphate and hippurate in human urine: INTERMAP Study","volume":"4","author":"Wijeyesekera","year":"2012","journal-title":"Anal. Methods"},{"key":"10.1016\/j.ymgme.2017.08.011_bb0080","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0009-8981(99)00004-2","article-title":"The assay of phenylacetic acid and 4-phenylbutyric acid in physiological fluids","volume":"284","author":"Hommes","year":"1999","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgme.2017.08.011_bb0085","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ab.2010.01.010","article-title":"Identification of phenylbutyrate-generated metabolites in Huntington disease patients using parallel LC\/EC-array\/MS and off-line tandem MS","volume":"399","author":"Ebbel","year":"2010","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ymgme.2017.08.011_bb0090","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jchromb.2012.07.004","article-title":"Determination of phenylbutyric acid and its metabolite phenylacetic acid in different tissues of mouse by liquid chromatography with tandem mass spectrometry and its application in drug tissue distribution","volume":"903","author":"Marahatta","year":"2012","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.ymgme.2017.08.011_bb0095","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/clinchem\/30.10.1664","article-title":"Reactionof picrate with creatinine and cepha antibiotic","volume":"30","author":"Kroll","year":"1984","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ymgme.2017.08.011_bb0100","article-title":"Suggested guidelines for the diagnosis and management of urea cycle disorders","volume":"7","author":"H\u00e4berle","year":"2012","journal-title":"Otphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2017.08.011_bb0105","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/gim.2014.148","article-title":"Blood ammonia and glutamine as predictors of hyperammonemic crises in patients with urea cycle disorder","volume":"17","author":"Lee","year":"2015","journal-title":"Genet. Med."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719217303323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719217303323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T16:42:31Z","timestamp":1719420151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719217303323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S1096719217303323"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2017.08.011","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantitation of phenylbutyrate metabolites by UPLC-MS\/MS demonstrates inverse correlation of phenylacetate:phenylacetylglutamine ratio with plasma glutamine levels","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2017.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}